Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) President Sells 2,800 Shares of Stock

Key Points

• President Ross Muken sold 2,800 shares on April 14 at an average price of $4.96 (≈$13,888), a transaction disclosed in an SEC filing and executed under a pre-arranged Rule 10b5-1 plan; he still owns 682,432 shares (a 0.41% reduction).
• The April sale is part of several recent planned insider disposals totaling roughly 40k–45k shares to cover tax withholding from vested awards, which are 10b5-1 trades that typically reduce negative interpretation but increase near-term float.
• Financially, SOPH recently missed EPS expectations and shows negative margins and ROE, yet analysts (Guggenheim, BTIG) have raised price targets and a Mount Sinai collaboration offers a commercial reference that could support adoption and revenue growth.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) President Ross Muken sold 2,800 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $4.96, for a total value of $13,888.00. Following the completion of the transaction, the president owned 682,432 shares in the company, valued at approximately $3,384,862.72. The trade was a 0.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, April 13th, Ross Muken sold 4,442 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $21,143.92.
• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.69, for a total value of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,484.24.
• On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total value of $11,804.88.
• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $5,666.57.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH traded up $0.05 during trading hours on Thursday, reaching $5.12. The stock had a trading volume of 125,040 shares, compared to its average volume of 181,146. The firm has a market cap of $350.67 million, a price-to-earnings ratio of -10.04 and a beta of 1.04. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01. SOPHiA GENETICS SA has a fifty-two week low of $2.58 and a fifty-two week high of $5.70. The firm has a 50-day moving average of $4.74 and a 200-day moving average of $4.72.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Equities research analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Guggenheim upped their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research report on Monday, January 26th. BTIG Research upped their target price on SOPHiA GENETICS from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $7.50.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Mount Sinai collaboration: Mount Sinai Health System will adopt SOPHiA’s AI-powered SOPHiA DDM™ platform to accelerate genomic testing and precision oncology research — a meaningful commercial reference that can drive platform adoption, revenue growth and credibility with other academic centers. Mount Sinai collaboration
• Positive Sentiment: Analyst support: Recent analyst activity includes price-target increases and buy ratings (e.g., Guggenheim and BTIG raising targets toward ~$7), which can attract demand from institutional and retail buyers. Analyst notes
• Neutral Sentiment: Insider selling under 10b5-1 plans: Several executives (CEO Jurgi Camblong, President Ross Muken, others) executed planned sales totaling roughly ~40k–45k shares to cover tax withholdings tied to vested awards. Trades were pre-arranged 10b5-1 sales, which typically reduces negative interpretation but still increases float in the short term. SEC Form 4 (CEO)
• Neutral Sentiment: Sector tailwind / industry validation: Coverage about Mount Sinai and other health systems using AI to speed genomic testing highlights growing market demand for AI-driven genomics platforms, supporting SOPH’s TAM and adoption case. HealthcareITNews
• Negative Sentiment: Recent fundamentals and profitability headwinds: SOPH reported a March quarter EPS miss (reported loss per share larger than consensus) and continues to show negative margins and ROE, which remain risks for near-term valuation and require revenue traction to justify higher targets. Quarterly results & profile

Institutional Investors Weigh In On SOPHiA GENETICS

Hedge funds have recently modified their holdings of the stock. Silverberg Bernstein Capital Management LLC increased its stake in SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company's stock valued at $257,000 after buying an additional 4,155 shares during the period. Green Alpha Advisors LLC raised its position in SOPHiA GENETICS by 10.8% during the 4th quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company's stock worth $213,000 after buying an additional 4,444 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock worth $148,000 after acquiring an additional 6,205 shares during the period. Savvy Advisors Inc. acquired a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth $48,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS in the third quarter valued at about $49,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.